Huadong Medicine Receives Multiple Capital Market Honors, Recognized for Comprehensive Strength

In the “2025 New Fortune Best Listed Companies” awards recently announced by New Fortune magazine, Huadong Medicine won two prestigious honors—“Best Listed Company” and “Best ESG Practice Company”—thanks to its solid operational performance, continuous innovation breakthroughs, and leading sustainable development practices.

According to the introduction, the event was conducted in two phases. In the first phase, New Fortune magazine and the Guanghua-Rotman Information and Capital Markets Research Center constructed the “China Listed Company Information Transparency Index” based on questionnaire surveys and big data analysis. A shortlist was then released by comprehensively evaluating this index along with scores for financial performance, brand value, and ESG ratings. In the second phase, through due diligence, site visits, and voting, the final rankings were determined by combining the scores from both phases, resulting in the selection of the “Top 100 Best Listed Companies,” alongside the identification of 50 “Best ESG Practice Companies.”

In terms of ESG governance, Huadong Medicine has established a three-tier governance structure comprising the Board of Directors, the Sustainability (ESG) Committee, and the ESG Working Group, to ensure the systematic and regular advancement of sustainability initiatives, and has consistently disclosed its annual ESG report for nine consecutive years.

On June 26, 2026, the 17th Listed Company Investor Relations Management Forum, hosted by Securities Times, was held in Shenzhen, and the winners of the “17th Listed Company Investor Relations Management Tianma Awards” were officially announced. Huadong Medicine swept three major awards: the company won the “Listed Company Investor Relations Management Tianma Award,” Chairman Lü Liang received the “Sunshine Governance Leader of Listed Companies” award, and Board Secretary Chen Bo was honored with the “Outstanding Board Secretary for Investor Relations Management of Listed Companies” award.

The “Pegasus Award for Investor Relations Management of Listed Companies,” hosted by Securities Times, is one of the earliest authoritative awards in China’s mainstream financial media dedicated to investor relations management in the capital market. Since its inception in 2009, the award has been successfully presented for seventeen editions. This year’s selection attracted self-nominations from over 2,300 listed companies, setting a new record. The newly added “Sunshine Governance Leader of Listed Companies” award focuses on the highest decision-making level of listed companies, aiming to honor chairpersons who attach great strategic importance to and personally drive investor relations management, thereby leading their companies to foster a proactive and transparent governance culture.

In recent years, the Board Office of Huadong Medicine has strictly ensured compliant operations and standardized the functioning of the “Three Meetings” (Shareholders’ General Meeting, Board of Directors Meeting, and Supervisory Committee Meeting), while establishing a systematic and professional investor relations management mechanism. The Company comprehensively, accurately, and timely communicates its operational information to investors through various channels, including the Interactive Easy platform, earnings briefings, research visits, roadshows, and Investor Reception Days.

On June 25, 2026, the eighth edition of the “Top 100 Innovative Pharmaceutical Enterprises in China 2026” list, released by E-Drug Manager, ranked Huadong Medicine in the first tier, recognizing its robust R&D investment and innovative achievements.

The list has been published for eight consecutive years since 2019. Based on comprehensive data, it evaluates performance across three dimensions—foundation of innovation, innovation process, and innovation outcomes—using four key indicators: the number of core patents granted for innovative drugs, the number of peripheral patents granted, the number of clinical trials conducted, and the number of innovative drugs approved and launched.

Huadong Medicine has been deeply engaged in the pharmaceutical and healthcare industry for over three decades, with business covering the entire pharmaceutical industry chain. The company operates four major segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology. In 2025, the company achieved operating revenue of RMB 43.612 billion, a year-on-year increase of 4.07%, and net profit attributable to shareholders of the parent company of RMB 3.414 billion. In the first quarter of 2026, operating revenue reached RMB 11.183 billion, a year-on-year increase of 4.17%, while net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses amounted to RMB 990 million, representing a year-on-year increase of 10.30%, thereby maintaining a steady and positive development trend.

The Company has continued to increase its R&D investment. In 2025, the R&D expenditure of its pharmaceutical manufacturing segment (excluding equity investments) amounted to RMB 2.982 billion, representing a year-on-year increase of 11.36%. Of this, direct R&D expenditures totaled RMB 2.472 billion, a year-on-year increase of 39.64%, accounting for 16.60% of the pharmaceutical manufacturing segment’s revenue, placing the Company among the industry leaders in R&D intensity. The Company’s innovative drug R&D center is currently advancing 96 innovative drug pipeline projects, with a focus on core therapeutic areas including oncology, endocrinology, and autoimmune diseases. Revenue from innovative products reached RMB 2.34 billion in 2025, a year-on-year increase of 64.2%, and maintained a high growth rate of over 60% in the first quarter of 2026.